Launches And International Sales Propel Growth For Teligent Despite Bumpy Year

In 2018, product launches and growth in International sales enabled Teligent to post a group sales rise of almost a tenth to US$65.9 million, despite price erosion and serialization requirements impacting the business. Teligent expects its expanded US manufacturing facility in Buena, New Jersey, to be inspected by the FDA in the first half of 2019, with its first injectable to be launched from the site by the end of the year.

BlueHills
Teligent achieved growth in 2018 despite facing some bumps along the way • Source: Shutterstock

Teligent’s group sales rose by 9% to US$65.9 million in 2018 as the firm said it “enjoyed robust growth” that was “fueled by product launches and our international operations”. International sales soared by over half, while US topical turnover climbed by nearly a fifth.

“Clearly, price erosion has been a common theme over the past couple of years,” president and chief executive officer Jason...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business